First in Human Study of AZD9592 in solid tumors

Trial Identifier: D9350C00001
Sponsor: AstraZeneca
NCTID:: NCT05647122
Start Date: December 2022
Primary Completion Date: October 2024
Study Completion Date: October 2024
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Melbourne, AU, 3000
CN Guangzhou, CN, 510100
ES Barcelona, ES, 8035
ES Madrid, ES, 28040
ES Sevilla, ES, 41013
JP Chuo-ku, JP, 104-0045
JP Kashiwa, JP, 277-8577
US, CA Duarte, CA, US, 91010
US, CA Irvine, CA, US, 92618
US, IL Chicago, IL, US, 60637
US, New York New York, US, 10029
US, NY Mineola, NY, US, 11501
US, NY New York, NY, US, 10021
US, PA Philadelphia, PA, US, 19104
US, RI Providence, RI, US, 02903
US, TX Houston, TX, US, 77030
US, VA Fairfax, VA, US, 22031